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Abstract: Objective: To screen pregnant women at risk of severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during delivery 
using reverse-transcription polymerase chain reaction (RT-PCR) test and 
serum immunoglobulin (Ig) testing. 
Method: Between March 31st and August 31st of 2020, consecutive pregnant 
women admitted for labor and delivery in a single hospital were screened 
for SARS-CoV-2 with nasopharyngeal RT-PCR swab tests and detection of 
serum IgG and IgM. 
Results: We studied 266 pregnant women admitted for labor and delivery. 
The prevalence of acute or past SARS-CoV-2 infection was 9.0 %, including 
(i) two cases with respiratory symptoms of SARS-Co-V-2 infection and 
positive RT-PCR; (ii) four asymptomatic women with positive RT-PCR 
without clinical symptoms and negative serological tests between two and 
15 weeks later; and (iii) two women with false positive RT-PCR due to 
technical problems. All newborns of the 6 pregnant women with RT-PCR 
positive had negative RT-PCR and did not require Neonatal Intensive Care 
Unit admission. There were eighteen asymptomatic women with positive 
serological IgG tests and negative RT-PCR.  
Conclusion: In our cohort of gravids, we found 2.2% of women with 
positive RT-PRC tests and 6.7% with positive serological tests during the 
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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) universal screening 
in gravids during delivery: Detection of virus and antibodies  
 
 


















































































Objective: To screen pregnant women at risk of severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) infection during delivery using reverse-transcription 
polymerase chain reaction (RT-PCR) test and serum immunoglobulin (Ig) testing. 
Method: Between March 31st and August 31st of 2020, consecutive pregnant women 
admitted for labor and delivery in a single hospital were screened for SARS-CoV-2 with 
nasopharyngeal RT-PCR swab tests and detection of serum IgG and IgM. 
Results: We studied 266 pregnant women admitted for labor and delivery. The prevalence 
of acute or past SARS-CoV-2 infection was 9.0 %, including (i) two cases with respiratory 
symptoms of SARS-Co-V-2 infection and positive RT-PCR; (ii) four asymptomatic 
women with positive RT-PCR without clinical symptoms and negative serological tests 
between two and 15 weeks later; and (iii) two women with false positive RT-PCR due to 
technical problems. All newborns of the 6 pregnant women with RT-PCR positive had 
negative RT-PCR and did not require Neonatal Intensive Care Unit admission. There were 
eighteen asymptomatic women with positive serological IgG tests and negative RT-PCR.  
Conclusion: In our cohort of gravids, we found 2.2% of women with positive RT-PRC 
tests and 6.7% with positive serological tests during the first wave of the SARS-CoV-2 
pandemic.  
Keywords: SARS-CoV-2; COVID-19; delivery; reverse-transcription polymerase chain 







































































There are several strategies to diagnose the severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) infection related to coronavirus disease (COVID-19) and to 
identify the current or past infection and immune status. The preferred primary method for 
screening is the reverse-transcription polymerase chain reaction (RT-PCR) using upper 
respiratory samples via nasopharyngeal or oropharyngeal swabs [1,2]. The procedure has 
been demonstrated to be highly specific (95%) [3,4] and sensitive (70%) in samples from 
non-pregnant women [4]. The RT-PCR may detect the current or past presence of viral 
material whereas the serological tests assess the formation of antibodies to SARS-CoV-2 
and may help to demonstrate a current infection [5]. The antibody tests for serum 
immunoglobulin (Ig) M (IgM), IgG, and IgA are based in the demonstration of those 
antibodies in human serum as a diagnostic tool of SARS-Co-V-2. These antibodies can be 
demonstrated in blood samples of patients RT-PCR positive 2-12 days after symptoms 
started and depending on sociodemographic factors [6].  
In asymptomatic pregnant women admitted for delivery, the reported positive 
SARS-COV-2 screening with the RT-PCR tests is 86-88%, which is similar to those in the 
general population [7,8]. However, the prevalence of those positive tests are variable 
depending on the study location and delivery facilities [8-12]. There are different 
techniques for antibody titration against SARS-CoV-2, including rapid IgM-IgG antibody 
tests, chemiluminescence immunoassay, and enzyme-linked immunosorbent assay 
(ELISA), and. The ELISA technique has a sensitivity of 89% and a specificity of 91% 
[13], although it varies according on the day of analysis since symptoms onset [14]. 
The objective of the present study is to evaluate the clinical manifestations and the 
performance of two different tests, RT-PCR and serological testing, for screening of 
pregnant women admitted to the maternity ward for delivery.  
 
2. Methods  





 of August, 2020, at the Hospital Universitario General de Villalba, located 
in the North of Madrid which attends 700-800 deliveries per year. The study was approved 
by the Fundación Jiménez Díaz Clinical Research Ethics Committee, Madrid, Spain 
(protocol EO107-20). A total of 266 pregnant women admitted to labor and delivery and to 




































































PCR in nasopharyngeal swabs and by a rapid blood antibodies rapid test. In cases with 
positive RT-PCR or positive antibodies rapid test for IgM and/or IgG, serological testing 
by ELISA was also carried out to confirm the results. 
The RT-PCR measurements were carried out using the MagMAX Viral/Pathogen II 
Nucleic Acid Isolation reagents in a KinGFisher Flex Purification System. PCR reagents 
were the Viasure SARS-CoV-2 real time RT-PCR detection it measured in a Bio-Rad 
CFX96 platform (TaqPath™ COVID-19 Combo Kit Multiplex Real Time RT-PCR). The 
rapid antbody test is a lateral flow immunochromatographic assay carried out using the test 
Biozek COVID-19 IgG/IgM Rapid Test Cassette. The ELISA serological presence of Igs 
was determined for IgG with Abbott reactive and for IgM with Vircell reactive. 
We collected demographic, clinical (fever, cough, rhinorrhea, dyspnea, chest pain, 
diarrhea, myalgia, new anosmia or ageusia), obstetric and perinatal data for each woman 
admitted, as well as, RT-PCR and serological results. Every woman was classified in one 
of the three SARS-CoV-2 categories: (i) acute infection (positive RT-PCR); (ii) healed 
women (negative RT-PCR with positive IgG); (iii) and never infected women (both 
negative RT-PCR and IgG). 
 
 
3. Results   
During the period of the study, 266 pregnant women admitted for labor and 
delivery were submitted to the SARS-Co-V-2 screening with RT-PCRs. The prevalence of 
acute or healed COVID-19 infection was 9.0 %, corresponding to 18 past SARS-CoV-2 
exposures and six current infections (Figure 1).  
There were eight positive RT-PCR for SARS-CoV-2, although two of them were 
categorized as laboratory misinterpretation of results after women were discharged from 
the hospital. As expected, these two cases had no clinical symptoms and were negative for 
ELISA antibody tests. Therefore, we finally counted six positive RT-PCR women, of 
whom two had COVID-19 symptoms during labor or delivery (one patient was only IgM 
positive and the other had no serological test), and four were asymptomatic (Table 1). One 
of the two symptomatic cases with positive RT-PCR was diagnosed with intrauterine 
growth restriction. The four asymptomatic and positive RT-PCR pregnant women were 
negative in the ELISA study for both IgM and IgG during hospitalization. These four cases 
were submitted to second ELISA immune tests five to 15 weeks after delivery being 




































































newborn required for admission to the Neonatal Intensive Care Unit, and also they all were 
RT-PCR negative. Symptomatic women were discharged on the third day and evolved 
favorably, as did their newborns.  
All negative RT-PCR cases (n = 260) were asymptomatic throughout the whole 




In a group of 266 pregnant women SARS-CoV-2 exposure was screened with RT-
PCR tests during delivery. There were eight RT-PCR positive patients including two 
women with clinical evidence of SARS-CoV-2 infection, four past viral exposure and two 
false positive due to technical problems. All these 8 neonates were healthy without clinical 
signs of virus infection and negative RT-PCR tests. Serological IgG specific antibodies 
addressed against the SARS-CoV-2 were present in 18 women with negative RT-PCR 
tests. Therefore, the prevalence of acute or past SARS-CoV-2 infection was 9.0 % in our 
cohort, which is similar to the prevalence in non-pregnant subjects studied by 
seroprevalence in the Madrid area [15]. The maternal ELISA tests, in the four RT-PCR 
positive and asymptomatic, repeated 2-15 weeks after delivery were negative. 
 Dust et al. [16] reported the performance of different commercial SARS-CoV-2 
RT-PCR assays testing clinical samples and reference material, ranging the sensitivity 
from 24 copies/mL to 574/mL specimen. However, the RT-PCR sensitivity, specificity, 
and positive or negative predictive values are still very difficult to determine without clear 
gold standard tests for SARS-COV-2 [17]. Previous studies have described positive RT-
PCR in asymptomatic pregnant women rates ranging between 50% and 89% [8,9,11,12], 
our 66.7 % in our small sample seems to fit well within reported ranges. 
Different studies have addressed the false-negative rate of the RT-PCR tests, 
ranging from 17.0 to 63.0 % [18]. We did not have patients with negative RT-PCR and 
symptoms suggestive of COVID-19. Less information is available about the false positive 
rate. Cohen et al. [19] reported a 2.3% false-positive rate that was most likely related to 
contamination from other positive samples analyzed at the same time, target genes 
amplified from prior positive samples or positive controls, or misinterpretation of results. 
SARS-CoV-2 serological testing can usually demonstrate IgM from 5th until the 




































































still unknown for how long antibodies will be produced [20]. The serological test may 
reach a specificity of 98.7% depending on the timing of sampling [5].   
 SARS-CoV-2 serology is complementary to RT-PCR for the COVID-19 diagnosis 
during at least 14 days after clinical infection initiation [21]. In a meta-analysis, the pooled 
ELISA methods have a sensitivity of 84% for measuring IgG or IgM as compared to lateral 
flow immunoassays of 66.0% and chemiluminescent immunoassays of 97.8% in the 
general population [22]. Total antibody determination has low sensitivity during the first 
weeks with clinical symptoms (30.1%), increasing during the second week to reach the 
highest levels during the third week. There is limited information beyond 35 days post-
initiation of clinical symptoms [5].  
There is scarce information concerning the antibody formation dynamic in pregnant 
women with SARS-Co-V-2 infection around the period of delivery. In an unselected 
cohort of German pregnant women, Zollkau et al. [23] reported a total of 225 PCRs and 
180 IgG tests, finding only one case with a positive IgG test. We detected positive IgG 
serological tests in 18 asymptomatic women.  None of our asymptomatic patients with 
positive RT-PCR developed antibodies during the study period. Pregnant women are 
considered a relatively low-risk group for COVID-19 since they are generally young [24, 
25]. However, there are also results suggesting that SARS-Co-V-2 is more likely 
associated with some adverse clinical conditions due to anatomic and physiological 
changes during pregnancy [26]. In addition, preeclampsia, excessive body weight and 
socioeconomic disparities may be potential cofactors to worsen the obstetric and perinatal 
results [27]. On the other hand, pregnant women during their third trimester of gestation 
and labor may display atypical features, including the absence of fever as well as 
leukocytosis. From our own experience, in asymptomatic patients with positive RT-PCR 




 We had two false positive RT-PCR for misinterpreting the test during the period of 
maximum incidence of the pandemic and probably related to initial learning curve of the 
technique. The false positive RT-PCR results may have a negative impact on clinical 
practice and emotional for pregnant women and their families, increasing specific 
assistance for a suspicious women and epidemiological statistics. Previous studies have 




































































meta-analyzed studies reporting at least 100 negative RT-PCR tests with a global 3.2% rate 
for false positive results which could at least partially explain reports of large numbers of 
asymptomatic carriers of SARS-CoV-2.  
Our two positive RT-PCR women were asymptomatic during the follow up with 
and were negative in the control serological tests. We do not know if we have had any false 
negative RT-PCR in asymptomatic patients, although we did not have positive IgM 
serologies in these cases either. It is interesting to note that asymptomatic cases with 
positive RT-PCR have shown negative IgM and IgG SARS-COV-2 antibodies by ELISA 
testing during hospitalization and four weeks after. There are several possible explanations, 
including (i) false positive RT-PCR cases for sample contamination for the false negative 
of antibody testing cases; (ii) true positive RT-PCR patients that have not developed 
antibodies because of the theoretical B-cell response against SARS-COV-2  [28] or with 
lower viral load, which has been associated to lower rates of seropositivity  [29]. 
New methods are currently under development to detect SARS-CoV-2 combining 
simplified extraction of RNA with reverse transcription followed by isothermal 
amplification and clustered regularly interspaced short palindromic repeats mediated 
detection. This new approach has a sensitivity of 93.1% and a specificity of 98.5% [30]. 
   
Stregths of the study 
Our study point out the relevance in that RT-PCR and antibody serologies are 
techniques that can be complementary in some circumstances. In particular, antibodies 
would be indicated in symptomatic patients or with positive chest images with negative 
RT-PCR and in asymptomatic patients with positive RT-PCR to clarify false positives and 
negatives. The performance of antibodies has also allowed us to know which patients have 
overcome the disease. 
 
Conclusion 
 The pandemic nature of the COVID-19 has allowed designing different strategies to 
manage pregnant women according to available resources in different health care systems. 
We found that the systematic RT-PCR assessment and serological studies of SARS-CoV-2 
seem appropriated to identify women at risk during labor and delivery. There were 2.2% of 
women with positive RT-PRC tests and 6.7% with positive serological tests during the first 




































































international experiences to effectively define the better models of clinical assistance 
during pregnancy and delivery since the pandemic nature of the virus.  
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Tables and figures 
 
Table 1.  Reverse transcription polymerase chain reaction (RT-PCR) positive cases in 
pregnant women (n = 8/266) admitted for delivery, maternal and newborn outcomes, and 
analytical results. 
 





Table 1.  Reverse transcription polymerase chain reaction (RT-PCR) positive cases in pregnant women (n = 8/266) admitted for 






















and IgMa control 
(ELISAc) 
1 26, 2, 37 Yes (fever and cough) Vaginal Female 2525 7.28 10 + Not done Not done 
2 35, 1, 40 Yes (fever and cough) Vaginal Male 3480 7.30 10 + + / + Not done 
3 26, 3, 39 No Vaginal Female 3425 7.27 10 + Not done - (15 weeks) 
4 32, 0, 40 No Vaginal Male 2805 7.20 10 + - / - - (2 weeks) 
5 21, 0, 39 No Vaginal Male 3350 7.33 10 + + / - - (12 weeks) 
6 27, 0, 39 No Vaginal Female 3054 7.33 10 + - / - - (15 weeks) 
7 31, 0, 40 No 
Cesarean section 
(induction failure) Male 3950 7.31 10 
+ (false 
positive) - / - 
Not done 
8 25, 0, 41 No Vaginal Female 3915 7.19 9 
+ (false 




 IgM: immunoglobulin M 
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 IgG: immunoglobulin G 
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Abstract  35 
Objective: To screen pregnant women at risk of severe acute respiratory syndrome 36 
coronavirus 2 (SARS-CoV-2) infection during delivery using reverse-transcription 37 
polymerase chain reaction (RT-PCR) test and serum immunoglobulin (Ig) testing. 38 
Method: Between March 31st and August 31st of 2020, consecutive pregnant women 39 
admitted for labor and delivery in a single hospital were screened for SARS-CoV-2 with 40 
nasopharyngeal RT-PCR swab tests and detection of serum IgG and IgM. 41 
Results: We studied 266 pregnant women admitted for labor and delivery. The prevalence 42 
of acute or past SARS-CoV-2 infection was 9.0 %, including (i) two cases with respiratory 43 
symptoms of SARS-Co-V-2 infection and positive RT-PCR; (ii) four asymptomatic 44 
women with positive RT-PCR without clinical symptoms and negative serological tests 45 
between two and 15 weeks later; and (iii) two women with false positive RT-PCR due to 46 
technical problems. All newborns of the 6 pregnant women with RT-PCR positive had 47 
negative RT-PCR and did not require Neonatal Intensive Care Unit admission. There were 48 
eighteen asymptomatic women with positive serological IgG tests and negative RT-PCR.  49 
Conclusion: In our cohort of gravids, we found 2.2% of women with positive RT-PRC 50 
tests and 6.7% with positive serological tests during the first wave of the SARS-CoV-2 51 
pandemic.  52 
Keywords: SARS-CoV-2; COVID-19; labor and delivery; reverse-transcription 53 
polymerase chain reaction (RT-PCR); serum immunoglobulins; screening  54 
  55 
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1. Introduction 56 
There are several strategies to diagnose the severe acute respiratory syndrome 57 
coronavirus 2 (SARS-CoV-2) infection related to coronavirus disease (COVID-19) and to 58 
identify the current or past infection and immune status. The preferred primary method for 59 
screening is the reverse-transcription polymerase chain reaction (RT-PCR) using upper 60 
respiratory samples via nasopharyngeal or oropharyngeal swabs [1,2]. The procedure has 61 
been demonstrated to be highly specific (95%) [3,4] and sensitive (70%) in samples from 62 
non-pregnant women [4]. The RT-PCR may detect the current or past presence of viral 63 
material whereas the serological tests assess the formation of antibodies to SARS-CoV-2 64 
and may help to demonstrate a current infection [5]. The antibody tests for serum 65 
immunoglobulin (Ig) M (IgM), IgG, and IgA are based in the demonstration of those 66 
antibodies in human serum as a diagnostic tool of SARS-Co-V-2. These antibodies can be 67 
demonstrated in blood samples of patients RT-PCR positive 2-12 days after symptoms 68 
started and depending on sociodemographic factors [6].  69 
In asymptomatic pregnant women admitted for delivery, the reported positive 70 
SARS-COV-2 screening with the RT-PCR tests is 86-88%, which is similar to those in the 71 
general population [7,8]. However, the prevalence of those positive tests are variable 72 
depending on the study location and delivery facilities [8-12]. There are different 73 
techniques for antibody titration against SARS-CoV-2, including rapid IgM-IgG antibody 74 
tests, chemiluminescence immunoassay, and enzyme-linked immunosorbent assay 75 
(ELISA), and. The ELISA technique has a sensitivity of 89% and a specificity of 91% 76 
[13], although it varies according on the day of analysis since symptoms onset [14]. 77 
The objective of the present study is to evaluate the clinical manifestations and the 78 
performance of two different tests, RT-PCR and serological testing, for screening of 79 
pregnant women admitted to the maternity ward for delivery.  80 
 81 
2. Methods  82 
This observational retrospective cohort study was conducted between the 31
st
 of 83 
March and 31
st
 of August, 2020, at the Hospital Universitario General de Villalba, located 84 
in the North of Madrid which attends 700-800 deliveries per year. The study was approved 85 
by the Fundación Jiménez Díaz Clinical Research Ethics Committee, Madrid, Spain 86 
(protocol EO107-20). A total of 266 pregnant women admitted to labor and delivery and to 87 
scheduled procedures such as labor induction or caesarean delivery, were screened by RT-88 
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PCR in nasopharyngeal swabs and by a rapid blood antibodies rapid test. In cases with 89 
positive RT-PCR or positive antibodies rapid test for IgM and/or IgG, serological testing 90 
by ELISA was also carried out to confirm the results. 91 
The RT-PCR measurements were carried out using the MagMAX Viral/Pathogen II 92 
Nucleic Acid Isolation reagents in a KinGFisher Flex Purification System. PCR reagents 93 
were the Viasure SARS-CoV-2 real time RT-PCR detection it measured in a Bio-Rad 94 
CFX96 platform (TaqPath™ COVID-19 Combo Kit Multiplex Real Time RT-PCR). The 95 
rapid antibody test is a lateral flow immunochromatographic assay carried out using the 96 
test Biozek COVID-19 IgG/IgM Rapid Test Cassette. The ELISA serological presence of 97 
immunoglobulins was determined for IgG with Abbott reactive and for IgM with Vircell 98 
reactive. 99 
We collected demographic, clinical (fever, cough, rhinorrhea, dyspnea, chest pain, 100 
diarrhea, myalgia, new anosmia or ageusia), obstetric and perinatal data for each woman 101 
admitted, as well as, RT-PCR and serological results. Every woman was classified in one 102 
of the three SARS-CoV-2 categories: (i) acute infection (positive RT-PCR); (ii) healed 103 
women (negative RT-PCR with positive IgG); (iii) and never infected women (both 104 
negative RT-PCR and IgG). 105 
 106 
3. Results   107 
During the period of the study, 266 pregnant women admitted for labor and 108 
delivery were submitted to the SARS-Co-V-2 screening with RT-PCRs. The prevalence of 109 
acute or healed COVID-19 infection was 9.0 %, corresponding to 18 past SARS-CoV-2 110 
exposures and six current infections (Figure 1).  111 
There were eight positive RT-PCR for SARS-CoV-2, although two of them were 112 
categorized as laboratory misinterpretation of results after women were discharged from 113 
the hospital. As expected, these two cases had no clinical symptoms and were negative for 114 
ELISA antibody tests. Therefore, we finally counted six positive RT-PCR women, of 115 
whom two had COVID-19 symptoms during labor or delivery (one patient was only IgM 116 
positive and the other had no serological test), and four were asymptomatic (Table 1). One 117 
of the two symptomatic cases with positive RT-PCR was diagnosed with intrauterine 118 
growth restriction. The four asymptomatic and positive RT-PCR pregnant women were 119 
negative in the ELISA study for both IgM and IgG during hospitalization. These four cases 120 
were submitted to second ELISA immune tests five to 15 weeks after delivery being 121 
negative once again.  All six cases were vaginal deliveries without neonatal acidosis, no 122 
5 
 
newborn required for admission to the Neonatal Intensive Care Unit, and also they all were 123 
RT-PCR negative. Symptomatic women were discharged on the third day and evolved 124 
favorably, as did their newborns. All negative RT-PCR cases (n = 260) were asymptomatic 125 
throughout the whole hospitalization and 18 of them were positive for IgG, being 126 
considered as past SARS-CoV-2 exposure. 127 
 128 
4. Discussion 129 
In a group of 266 pregnant women SARS-CoV-2 exposure was screened with RT-130 
PCR tests during delivery. There were eight RT-PCR positive patients including two 131 
women with clinical evidence of SARS-CoV-2 infection, four past viral exposure and two 132 
false positive due to technical problems. All these 8 neonates were healthy without clinical 133 
signs of virus infection and negative RT-PCR tests. Serological IgG specific antibodies 134 
addressed against the SARS-CoV-2 were present in 18 women with negative RT-PCR 135 
tests. Therefore, the prevalence of acute or past SARS-CoV-2 infection was 9.0 % in our 136 
cohort, which is similar to the prevalence in non-pregnant subjects studied by 137 
seroprevalence in the Madrid area [15]. The maternal ELISA tests, in the four RT-PCR 138 
positive and asymptomatic, repeated 2-15 weeks after delivery were negative. 139 
 Dust et al. [16] reported the performance of different commercial SARS-CoV-2 140 
RT-PCR assays testing clinical samples and reference material, ranging the sensitivity 141 
from 24 copies/mL to 574/mL specimen. However, the RT-PCR sensitivity, specificity, 142 
and positive or negative predictive values are still very difficult to determine without clear 143 
gold standard tests for SARS-COV-2 [17]. Previous studies have described positive RT-144 
PCR in asymptomatic pregnant women rates ranging between 50% and 89% [8,9,11,12], 145 
our 66.7 % in our small sample seems to fit well within reported ranges. Different studies 146 
have addressed the false-negative rate of the RT-PCR tests, ranging from 17.0 to 63.0 % 147 
[18]. We did not have patients with negative RT-PCR and symptoms suggestive of 148 
COVID-19. Less information is available about the false positive rate. Cohen et al. [19] 149 
reported a 2.3% false-positive rate that was most likely related to contamination from other 150 
positive samples analyzed at the same time, target genes amplified from prior positive 151 
samples or positive controls, or misinterpretation of results. 152 
Fasset et al. [10] reported a retrospective cohort study of 3,923 asymptomatic 153 
pregnant women screened for SARS-CoV-2 at labor and delivery in 15 hospitals in 154 
Southern California, reporting 17 women with a positive RT-PCR test, 24 had a fever 155 
on admission, and none developed the viral infection during the following 14 days. 156 
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Besides, neonates were negative for SARS-CoV-2 tests during the first day 157 
postpartum. Vintzileos et al. [20] reported a retrospective cohort describing a 158 
screening program for all pregnant adolescents and women admitted in labor and 159 
delivery (n = 161) in a single Hospital in New York using RT-PCR tests. They found 160 
that 20% (n = 32) of admitted women were positive for SARS-CoV-2 infection and 161 
66% of these women were asymptomatic and all neonates were negative for viral 162 
infection. Another more recent publication reported prospective results from 3 other 163 
hospitals from New York including 675 women admitted at delivery [12]. They 164 
reported high rates of cesarean delivery in symptomatic COVID-19 (46.7%), 165 
asymptomatic COVID-19 (45.5%) and in women without COVID-19. In all these 3 166 
studies from the United States SARS-CoV-2 serological tests were not used. Knight et 167 
al. [21] reported clinical outcomes of 427 pregnant women with confirmed SARS-168 
CoV-2 infection from the United Kingdom National population cohort, including 169 
gravids admitted to hospital with confirmed SARS-CoV-2 infection by RT-PCR tests. 170 
SARS-CoV-2 serological testing can usually demonstrate IgM from 5th until the 171 
21st day of the infection and IgG within 10-20 days after the symptom onset, although it is 172 
still unknown for how long antibodies will be produced [22]. The serological test may 173 
reach a specificity of 98.7% depending on the timing of sampling [5]. SARS-CoV-2 174 
serology is complementary to RT-PCR for the COVID-19 diagnosis during at least 14 days 175 
after clinical infection initiation [23]. In a meta-analysis, the pooled ELISA methods have 176 
a sensitivity of 84% for measuring IgG or IgM as compared to lateral flow immunoassays 177 
of 66.0% and chemiluminescent immunoassays of 97.8% in the general population [24]. 178 
Total antibody determination has low sensitivity during the first weeks with clinical 179 
symptoms (30.1%), increasing during the second week to reach the highest levels during 180 
the third week. There is limited information beyond 35 days post-initiation of clinical 181 
symptoms [5]. Flannery et al. [6] performed serological tests in 1,293 women admitted 182 
at labor and delivery in Philadelphia, reporting that 6.2% had specific IgG and/or 183 
IgM against SARS-CoV-2. It is important to mention that of the 72 seropositive 184 
women, 46 (64%) were also RT-PCR positive. Haizler-Cohen et al. [25] postulated 185 
that PCR and serological tests may allow to establish the timing of infection: (i) the 186 
acute infection may displays a positive RT-PCR with negative serological testing; (ii) 187 
the past infection may have a negative RT-PCR and positive serological testing; (iii) 188 
when both tests are positive, the case may be a recent or past infection. It is accepted 189 
that a RT-PCR may remain positive for weeks after SARS-CoV-2 infection. 190 
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There is scarce information concerning the antibody formation dynamic in pregnant 191 
women with SARS-Co-V-2 infection around the period of delivery. In an unselected 192 
cohort of German pregnant women, Zollkau et al. [26] reported a total of 225 PCRs and 193 
180 IgG tests, finding only one case with a positive IgG test. We detected positive IgG 194 
serological tests in 18 asymptomatic women. None of our asymptomatic patients with 195 
positive RT-PCR developed antibodies during the study period. Pregnant women are 196 
considered a relatively low-risk group for COVID-19 since they are generally young [27, 197 
28]. However, there are also results suggesting that SARS-Co-V-2 is more likely 198 
associated with some adverse clinical conditions due to anatomic and physiological 199 
changes during pregnancy [29]. In addition, preeclampsia, excessive body weight and 200 
socioeconomic disparities may be potential cofactors to worsen the obstetric and perinatal 201 
results [30]. On the other hand, pregnant women during their third trimester of gestation 202 
and labor may display atypical features, including the absence of fever as well as 203 
leukocytosis. From our own experience, in asymptomatic patients with positive RT-PCR 204 
we have to review RT-PCR in search of false positives and take into account perform 205 
antibody tests. 206 
 207 
Limitations 208 
 We had two false positive RT-PCR for misinterpreting the test during the period of 209 
maximum incidence of the pandemic and probably related to initial learning curve of the 210 
technique. The false positive RT-PCR results may have a negative impact on clinical 211 
practice and emotional for pregnant women and their families, increasing specific 212 
assistance for a suspicious women and epidemiological statistics. Previous studies have 213 
reported both false positive and false negative rates for RT-PCR. Cohen and Kessel [19] 214 
meta-analyzed studies reporting at least 100 negative RT-PCR tests with a global 3.2% rate 215 
for false positive results which could at least partially explain reports of large numbers of 216 
asymptomatic carriers of SARS-CoV-2.  217 
Our two positive RT-PCR women were asymptomatic during the follow up with 218 
and were negative in the control serological tests. We do not know if we have had any false 219 
negative RT-PCR in asymptomatic patients, although we did not have positive IgM 220 
serologies in these cases either. It is interesting to note that asymptomatic cases with 221 
positive RT-PCR have shown negative IgM and IgG SARS-COV-2 antibodies by ELISA 222 
testing during hospitalization and four weeks after. There are several possible explanations, 223 
including (i) false positive RT-PCR cases for sample contamination for the false negative 224 
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of antibody testing cases; (ii) true positive RT-PCR patients that have not developed 225 
antibodies because of the theoretical B-cell response against SARS-COV-2  [31] or with 226 
lower viral load, which has been associated to lower rates of seropositivity  [32]. 227 
New methods are currently under development to detect SARS-CoV-2 combining 228 
simplified extraction of RNA with reverse transcription followed by isothermal 229 
amplification and clustered regularly interspaced short palindromic repeats mediated 230 
detection. This new approach has a sensitivity of 93.1% and a specificity of 98.5% [33]. 231 
   232 
Stregths of the study 233 
Our study point out the relevance in that RT-PCR and antibody serologies are 234 
techniques that can be complementary in some circumstances. In particular, antibodies 235 
would be indicated in symptomatic patients or with positive chest images with negative 236 
RT-PCR and in asymptomatic patients with positive RT-PCR to clarify false positives and 237 
negatives. The performance of antibodies has also allowed us to know which patients have 238 
overcome the disease.  239 
 240 
Conclusion 241 
The pandemic nature of the COVID-19 has allowed designing different strategies to 242 
manage pregnant women according to available resources in different health care systems. 243 
We found that the systematic RT-PCR assessment and serological studies of SARS-CoV-2 244 
seem appropriated to identify women at risk during labor and delivery. There were 2.2% of 245 
women with positive RT-PRC tests and 6.7% with positive serological tests during the first 246 
wave of the SARS-CoV-2 pandemic in Madrid. However, every diagnosis proposal 247 
should bring something meaningful for the clinical management of SARS-CoV 2 248 
infected patients. There is a need to contrast different international experiences to 249 
effectively define the better diagnostic model of clinical assistance during pregnancy 250 
and delivery since the pandemic nature of the virus. 251 
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